Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

Abstract

Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60, NOMO-1, NB4, NKM-1, K562, Daudi, and… (More)
DOI: 10.1038/sj.leu.2401851

Topics

9 Figures and Tables

Cite this paper

@article{Naito2000CalicheamicinconjugatedHA, title={Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines}, author={Kensuke Naito and Akira Takeshita and Kazuyuki Shigeno and Shinichi Nakamura and Seiichiro Fujisawa and Kaori Shinjo and Hideaki Yoshida and Kazunori Ohnishi and Masatomo Mori and Syouichi Terakawa and Ryuzo Ohno}, journal={Leukemia}, year={2000}, volume={14}, pages={1436-1443} }